Immunotherapy Product Animation
SCIENTIFIC ANIMATION | Consistent brand identity & scientific education
We created this medical animation for Spectrum Pharmaceuticals for their immunotherapy product, Poziotinib®. The animation begins with the mechanism of disease of EGFR-positive and HER2-positive cancers, exploring how mutations in these genes result in uncontrolled cancer cell growth.
Poziotinib® is an investigational, orally-administered, irreversible tyrosine kinase inhibitor targeting EGFR and HER2 with exon 20 insertion mutations. Pre-clinical studies indicate that Poziotinib® inhibits kinase activity of EGFR and HER2 with exon 20 insertion mutations, inhibiting proliferation, and promoting cancer cell death. Poziotinib® is in development for the treatment of Non-Small Cell Lung Cancer (NSCLC) and breast cancer.
This animation can be found on the Spectrum Pharmaceuticals website on the Poziotinib® product page.
Imagery from the animation can be found throughout the product page. In addition, animation imagery is also used for page banners on the website homepage and the product page.
Are you interested in seeing how our award-winning medical animation can help you?
Random42 constantly strives to innovate in the medical animation space. Get in touch for a consultation on your next project.
‘‘Extremely happy, everybody was great on the team. They answered all our questions and made it look easy. The end result is perfect. ’’
Executive Coordinator, Cellectar Biosciences
‘‘The presentation was dramatically enhanced by the video, which looked fantastic on the big screen. Thank you and the entire Random42 team for your excellent work and for getting the final edition to me in time for the conference. All very much appreciated! ’’
President and CEO, Vallum Corporation
‘‘The quality of the work produced by Random42 sets them apart and helps us quickly tell our scientific story more clearly. The high-quality production value is bolstered by their depth of knowledge. Together, that helps us tell the story of a complex disease and cell-based treatment and make it understandable to professionals and laypeople alike.’’
CEO, Brainstorm Cell Therapeutics
‘‘Working with the Random42 team was a seamless collaboration, where they exhibited great project management skills, clear & thoughtful communication, and delivered high-quality work that was visually appealing. Our team was impressed with the final products!’’
Medical Affairs, Phathom Pharmaceuticals